Sophiris Bio (SPHS) Stock Rating Reaffirmed by Maxim Group

Sophiris Bio (NASDAQ:SPHS)‘s stock had its “buy” rating reiterated by equities research analysts at Maxim Group in a research report issued on Wednesday, MarketBeat reports. They presently have a $5.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $6.00. Maxim Group’s price target would suggest a potential upside of 147.52% from the stock’s current price.

A number of other research firms have also recently issued reports on SPHS. ValuEngine upgraded shares of Sophiris Bio from a “strong sell” rating to a “sell” rating in a research note on Friday, December 15th. HC Wainwright set a $6.00 target price on shares of Sophiris Bio and gave the company a “buy” rating in a research note on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $6.00.

Sophiris Bio (NASDAQ SPHS) traded up $0.02 during trading hours on Wednesday, hitting $2.02. 181,084 shares of the stock were exchanged, compared to its average volume of 245,070. Sophiris Bio has a 52 week low of $1.80 and a 52 week high of $2.95. The company has a quick ratio of 13.37, a current ratio of 13.37 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $60.22, a PE ratio of -11.22 and a beta of 1.25.

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new stake in shares of Sophiris Bio in the fourth quarter valued at approximately $312,000. Virtu Financial LLC increased its holdings in shares of Sophiris Bio by 389.7% in the fourth quarter. Virtu Financial LLC now owns 169,790 shares of the biopharmaceutical company’s stock valued at $385,000 after purchasing an additional 135,119 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Sophiris Bio by 1.0% in the second quarter. Vanguard Group Inc. now owns 731,437 shares of the biopharmaceutical company’s stock valued at $1,609,000 after purchasing an additional 7,600 shares in the last quarter. Institutional investors own 5.52% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/sophiris-bio-sphs-stock-rating-reaffirmed-by-maxim-group.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply